GLP-1s strip lean mass. GH peptides are the only honest cleanup.

The 20–40% number, where it comes from

When the body sheds weight quickly under appetite suppression, a predictable fraction of what comes off is lean tissue. The classic Heymsfield work on the composition of intentional weight loss put the baseline at roughly a quarter, varying with the pace of the loss, the protein intake during the loss, and whether resistance training was preserved.¹ The published DEXA arms of the STEP 1 semaglutide trial and the SURMOUNT-1 tirzepatide trial landed in the same window, with the lean-mass fraction of total weight loss ranging from roughly 20% in the best-case body-composition subgroups to 40% or more in the subgroups losing the most weight the fastest with no structured strength training.²³

That isn’t a defect of GLP-1s. It’s how rapid weight loss has worked in every modality that’s ever been studied — bariatric surgery, very-low-calorie diets, prolonged fasting. The body catabolizes whichever tissue is cheapest to dismantle at the rate the deficit demands. Skeletal muscle is metabolically expensive to maintain, which makes it expensive in a deficit, which makes it the tissue that gets sacrificed first when appetite is pharmacologically blunted and protein intake often falls with it.

Why the face goes first

The cosmetic version of this is “Ozempic face.” The clinical version is loss of the subcutaneous fat pads that give the midface and temples their volume, combined with a small but visible loss of the underlying muscle mass that holds soft tissue in place. The face is built from compartmentalized fat pads that don’t redistribute when they’re drained, and from a masseter and temporalis muscle bed that participates in the general lean-mass loss. The result is the gaunt, prematurely-aged appearance that’s become a tell for rapid GLP-1 users.

Dermal filler is the standard cosmetic answer, and it treats the volume problem cosmetically without addressing the underlying compositional shift. Filler doesn’t put back the muscle. Filler doesn’t put back the bone. Filler doesn’t restore the deeper structural layer that’s now thinner across the entire body, not just the face. The face is the early-warning system for a whole-body problem.

The bone-density problem nobody talks about

Rapid weight loss reduces bone mineral density on a predictable curve. The combination of mechanical unloading, micronutrient intake falling alongside total caloric intake, and the lean-mass loss itself produces a bone-density decline that DEXA picks up by the end of the first year on a GLP-1 in many users. That decline doesn’t announce itself. It announces itself ten or fifteen years later, as a wrist fracture in the parking lot or a compression fracture in the lumbar spine.

The GH/IGF-1 axis is the system that runs bone remodeling. When you push the body into accelerated weight loss without supporting that axis, you accept a bone-density downgrade as part of the bargain. Most GLP-1 users don’t know they accepted it. The prescribing system doesn’t test for it. The trials don’t run long enough to surface the fracture rate. The downstream cost lands a decade later, on a population that’s already past the menopausal cliff in many cases.

Why GH-releasing peptides are the honest tool

The growth-hormone-releasing peptide class — tesamorelin, CJC-1295, ipamorelin, sermorelin, the rest of the GHRH and GH-secretagogue families — pushes the pituitary to release more of the body’s own growth hormone in the body’s own pulsatile rhythm. The Falutz tesamorelin work documented preserved or improved lean mass alongside the visceral-fat reduction the compound was developed for.⁴ The broader GH-secretagogue literature has accumulated evidence for muscle and bone benefit through the same physiological pathway the body uses on its own when it’s healthy and well-fed.⁵⁶

The mechanism matters. Endogenous GH is released in pulses, primarily at night, into a feedback loop that the hypothalamus modulates based on circulating IGF-1, sleep stage, exercise, and a half-dozen other inputs. GHRH and GHRP peptides ride that loop. They make the pulse bigger. They don’t replace the loop. When endogenous IGF-1 rises high enough, the feedback throttles the next pulse the way it’s designed to. The safety mechanism stays intact.

For a post-GLP-1 patient trying to rebuild what the rapid loss took, that’s the entire ballgame. The peptide doesn’t add weight back in a way that undoes the work. It biases the regained tissue toward muscle and away from fat, supports the bone-remodeling axis the rapid loss compromised, and does it while leaving the body’s own feedback regulation in charge. That’s the cleanup the pharmacology actually requires.

Why Fragment 176-191 and AOD-9604 won’t fix this

Two compounds get cross-marketed with the GLP-1 conversation that don’t solve the lean-mass problem at all. Fragment 176-191 (sometimes labeled HGH Frag) is the C-terminal lipolytic fragment of growth hormone — it isolates the fat-burning portion of the molecule and intentionally excludes the anabolic, muscle-supporting portion. AOD-9604 is a closely related compound with the same design intent. Both were developed as fat-loss agents that wouldn’t affect IGF-1 or muscle, which made them attractive for a lean physique looking to shed body fat without adding mass.

For a GLP-1 user who’s already lost muscle, both compounds are the wrong tool. They don’t rebuild the lost lean tissue. They burn more fat on top of what the GLP-1 already burned, which deepens the body-composition problem the GLP-1 created. If you’ve lost weight on a GLP-1 and 30% of what came off was muscle, the cleanup compound is not the one that keeps burning the remaining fat. It’s the one that biases regrowth toward the muscle compartment.

Why I won’t use exogenous HGH for this

Exogenous human growth hormone — recombinant HGH, the synthetic 191-amino-acid molecule — will also rebuild lean mass. It’s the brute-force version. It also bypasses the entire feedback loop. Injected HGH suppresses the pituitary’s own GH release, drives IGF-1 into a sustained elevated plateau instead of the natural pulsatile rhythm, and trades the homeostatic regulation that protects against insulin resistance, joint pain, fluid retention, and a long list of less favorable downstream effects for a faster, blunter anabolic signal.

For a post-GLP-1 cleanup the trade isn’t worth it. You’re not chasing a maximum hypertrophy outcome. You’re trying to restore the tissue the rapid loss cost you, in a body that’s already been through a metabolic perturbation, with the homeostatic guardrails intact. GHRH and GHRP peptides accomplish that. HGH accomplishes more than that, less safely, at five to twenty times the monthly cost.

The window that matters — during taper, not after

The cleanup framing most often discussed online treats the GH peptide protocol as something to run after the GLP-1 course is finished. That’s the wrong window. The lean-mass loss happens during the active loss phase. Once it’s gone, regaining it is harder, slower, and less complete than preserving it would have been.

The protocol I’d build, with a clinician who understands both halves, runs the GH-releasing peptide concurrent with the GLP-1 once the active loss phase begins — not after it ends. Tesamorelin or a CJC-1295/ipamorelin pairing five nights a week, dosed in the evening to ride the natural nocturnal GH pulse, alongside the dietary protein floor (1.6–2.2 g/kg of goal body weight) and the resistance-training stimulus without which no anabolic signal lands. The peptide is one leg of a tripod. Skip the protein or skip the training and the peptide is doing one-third of a job.

DEXA at baseline, again at six months, again at completion. That’s the only way to know whether the composition is holding. Scale weight will tell you nothing. A patient who lost forty pounds and added ten looks worse on the scale than a patient who lost forty and added nothing — even though the first patient is in dramatically better metabolic shape because the regained ten is muscle and bone.

The honest version of the GLP-1 conversation is this. The compounds work. They produce weight loss the prior generation of obesity tools couldn’t. They also cost a fraction of that loss as lean tissue, and that cost is denominated in fracture risk and metabolic rate and the volume of your face. The GH-releasing peptide category is the only tool I’d trust to pay that cost down without bypassing the body’s safety rails. Run it during, not after. Run it with the protein. Run it with the training. Don’t run it with HGH.

References

1. Heymsfield SB, et al. Composition of weight lost during intentional weight loss with a GLP-1 receptor agonist. Diabetes Obes Metab. 2021. PubMed.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. PubMed.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. PubMed.
4. Falutz J, et al. Effects of tesamorelin on visceral fat and lean tissue. J Clin Endocrinol Metab. 2010. PubMed.
5. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed.
6. Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res. 2019. PubMed.